On the Radar Reports

Helping To Discover “Needle In A Haystack” Drugs, This Company’s Potential Is “Truly Mouthwatering”

“The company highlighted in today’s article “helps its customers to find the exceedingly rare cells/antibodies needed to fight cancer, inflammation etc. Basically, to find the needle in the haystack” – and as it operates in a high-growth and rapidly expanding area of biotech, the author believes that this digital cell biology company is a solid candidate for high-growth/high-risk portfolios. For… 

This Under-The-Radar Pharmaceutical Sales Disruptor Is A Multi-Bagger Stock

“It’s a small cap, a billion-dollar company, 100% revenue growth, and it’s small and it’s unknown,” says the author of today’s article of the pharmaceutical marketing company he highlights, which is disrupting the way that drugs are traditionally sold to physicians – and has become a multi-bagger stock in the process. For more on this “under-the-radar pic for investors who…have… 

5 Energy Stocks Under $10 With Solid Alpha Potential

“While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article of the five Buy-rated energy stocks trading under $10 that he proceeds to highlight.… 

Upcoming PDUFA Dates Could Be Major Catalysts For These 3 Biotech Stocks

In the biotech realm, the author of today’s article notes that “PDUFA (Prescription Drug User Fee Act) dates – the deadline of the FDA’s review of new drugs – determine whether a treatment is fit for purpose or not and a yay or nay can act as a major catalyst to send shares either soaring or crashing.” As such, he… 

4 Stocks To Play This “Hot Technology Silo”

Of the four stocks highlighted in today’s article, the author declares them “outstanding ideas for aggressive growth investors looking to add this hot technology silo.” The silo in question? Cybersecurity and analytics, which, in a new research report, Goldman Sachs is very positive on. For four top new trends in cybersecurity and analytics that Goldman noted in its report, as… 

3 Small-Cap Stocks Showing Strong Technical Performance

While large-cap stocks receive more attention from analysts and more investment, the author of today’s article reminds the reader that “small caps, over time, outperform their larger peers.” With that, she proceeds to highlight three small-cap stocks that are showing strong technical performance – including, in the biotech arena, a genetic-testing specialist. For more, CLICK HERE.

A “Better Than Bitcoin” Biotech Bet

With several exciting product candidates in its pipeline that could achieve blockbuster status, the author of today’s article believes that the clinical-stage biotech that he highlights, which is focused on developing treatments for disorders that affect the central nervous system, is a better bet than an investment that’s all the rage these days: bitcoin. For the biotech in question and… 

These Marijuana Stocks Are Analysts’ Favorites

While the best way to ride the marijuana legalization wave may be through exchange-traded funds, for those interested in specific stock ideas, which marijuana stocks are analysts’ favorites? Today’s article sifts through the holdings of the six largest marijuana ETFs to identify them. For a list of these marijuana stocks and their respective upside potential, CLICK HERE.

“Stockpicker’s Paradise”: 2 “Strong Buy” Penny Stocks With Upside Potential Over 200%

“We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain,” asserts one small/mid-cap stock strategist cited in today’s article, which proceeds to highlight two penny stocks that boast “Strong Buy” consensus ratings and upside potential over 200%. For these two penny stocks, CLICK HERE.

These 5 Stocks Cost Little And Have “Mammoth Upside Potential”

“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” declares the author of today’s article of the five Buy-rated stocks trading under $10 that he highlights. Among them are a late-stage pharmaceutical company focused on developing potential new therapies for cancer, a security technology company that provides email encryption…